SCHEMBL14378232

SCHEMBL14378232

CCS(=O)(=O)Cc1ccc(F)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.44
AGXT P21549 2/20 0.44
HTR2A P28223 6/20 0.43
HTR2C P28335 6/20 0.43
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
RIPK1 Q13546 2/20 0.42
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
KDM4E B2RXH2 2/20 0.40
MAOB P27338 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KCNH2 Q12809 3/20 0.39
DAO P14920 1/20 0.38
ALDH1A1 P00352 3/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4518776 0.90 IDO1 (0.48) IDO1AGXTHTR2AHTR2CPTGS1
SCHEMBL14426961 0.87 IDO1 (0.41) IDO1AGXTHTR2AHTR2CPTGS1
SCHEMBL14378223 0.85 PSEN1 (0.56) RIPK1PSEN1PSEN2APH1BNCSTN
SCHEMBL1271805 0.82 PTGS2 (0.47) IDO1AGXTHTR2AHTR2CPTGS1
SCHEMBL18571256 0.80 IDO1 (0.41) IDO1AGXTHTR2AHTR2CPTGS1
SCHEMBL469184 0.79 IDO1 (0.54) IDO1AGXTHTR2AHTR2CRIPK1
SCHEMBL14378240 0.79 IDO1 (0.50) IDO1
SCHEMBL1271804 0.78 IDO1 (0.46) IDO1AGXTHTR2AHTR2CPTGS1
SCHEMBL1972231 0.78 IDO1 (0.46) IDO1AGXTHTR2AHTR2CPTGS1
SCHEMBL3229354 0.78 IDO1 (0.50) IDO1AGXTHTR2AHTR2CPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
US-20070232654-A1 Novel Compounds and Compositions as Cathepsin Inhibitors AXYS PHARMACEUTICALS, INC. (US) 2007-10-04 US disclosed
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE IDO1 3719/4885AGXT 3552/4885HTR2A 4443/4885
US-20070232654-A1 Novel Compounds and Compositions as Cathepsin Inhibitors CTSS, CTSB, CTSE IDO1 3719/4885AGXT 3552/4885HTR2A 4443/4885
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA IDO1 221/4885AGXT 3766/4885HTR2A 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.